Aim: The present study aimed to determine the proportion of rheumatoid arthritis (RA) patients with sarcopenic obesity and to identify associated factors through assessments of physical function and patient-reported outcomes (PROs).
Methods: A prospective cohort study of 321 RA patients aged 40-79 years was conducted. Participants were classified into four groups-Normal, Obesity, Sarcopenia, and Sarcopenic obesity-based on sarcopenia criteria, which included skeletal muscle mass index, grip strength, and physical function, as well as obesity criteria defined by body fat percentage.
Objective: This study aimed to evaluate the relationship between laughter frequency, disease activity, physical function, and frailty in rheumatoid arthritis (RA) patients.
Methods: A total of 679 consecutive RA patients from a multicenter observational study conducted in 2023 were included. Laughter frequency was assessed using a standardized questionnaire, and patients were divided into the following four laughter frequency groups: 'almost every day,' '1-5 days per week,' '1-3 days per month,' and 'never or almost never.
We compared the efficacy of romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis in a randomized controlled trial. A total of 112 participants aged 75-90 years were randomized equally into the romosozumab and denosumab groups. Among these, 49 and 52 participants, respectively, who received their initial dose were included in the analysis.
View Article and Find Full Text PDFInt J Rheum Dis
July 2025
Objective: To evaluate vertebral Hounsfield Unit (HU) values on computed tomography (CT) in patients with ankylosing spondylitis (AS) compared to patients without AS and to examine differences in HU values between ankylosed and nonankylosed vertebrae in patients with AS.
Methods: This cross-sectional study included 34 patients with AS and 73 patients without AS who underwent spinal CT between 2004 and 2022. HU values were measured from C3 to L5 in patients with AS and from L1 to L5 in patients without AS.
Background: Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in MTX-naïve patients. However, comparisons in patients with an inadequate response to MTX remain unclear.
View Article and Find Full Text PDFAim: To compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).
Methods: This retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan-Meier curves, with the log-rank test for between-group comparisons.
Objectives: This study aims to investigate the association between frailty and oral function in rheumatoid arthritis (RA) patients and to identify practical markers for early frailty detection and potential intervention strategies.
Patients And Methods: A multi-center observational cohort study (T-FLAG) included a total of 661 RA patients (186 males, 475 females; mean age: 68.5±13.
Objectives: To examine risk factors for non-frailty rheumatoid arthritis (RA) patients progressing to frailty.
Methods: A total of 304 RA patients with records for frailty assessment based on the Japanese Cardiovascular Health Study (J-CHS) criteria from 2020 to 2024 were included. Patients classified as non-frail (J-CHS scores 0-3) in 2020 were followed annually, and those who did and did not progress to frailty were categorized into the frailty progression (n = 100) and non-frailty progression (n = 204) groups, respectively.
Objective: The present non-inferiority study was designed to compare the effect of discontinuing versus continuing methotrexate (MTX) alongside certolizumab pegol (CZP) on maintaining low disease activity (LDA) in rheumatoid arthritis (RA) patients already stable on combination therapy.
Methods: This multicentre, open-label, randomised, controlled trial included RA patients with sustained LDA (Clinical Disease Activity Index [CDAI] ≤ 10) for ≥ 12 weeks with CZP + MTX. Patients were randomised 1:1 by computer to either continue MTX (CZP + MTX group) or discontinue MTX after a 12-week reduction period (CZP group) using a dynamic allocation strategy with the minimisation method.
Objective: Peripheral helper T (Tph) cells, together with plasma cells, are the major pathogenic lymphocytes in the synovium in rheumatoid arthritis (RA). However, whether these cells are involved in RA-associated lung and/or airway disease is unknown.
Methods: Tph cells in sputum were analyzed by flow cytometry and compared with those in synovial fluid and synovial tissue.
Objective: This study aimed to examine relationships of the degree and level of spinal ankylosis with spinal mobility and functional impairment in patients with radiographic axial spondyloarthritis (r-axSpA) using computed tomography (CT).
Methods: This retrospective study involving 27 patients examined the number of fused intervertebral segments in the whole, cervical, thoracic, and lumbar spine using CT as a measure of spinal ankylosis, Bath Ankylosing Spondylitis Metrology Index (BASMI) as a measure of spinal mobility, and Bath Ankylosing Spondylitis Functional Index (BASFI) as a measure of functional impairment.
Results: Significant positive correlations were found between both BASMI and BASFI and the number of fused intervertebral segments in the whole, cervical, thoracic, and lumbar spine.
Objectives: To identify factors associated with probable sarcopenia in patients with rheumatoid arthritis (RA).
Methods: Probable sarcopenia was diagnosed using the SARC-F questionnaire. Patients with difficult-to-treat RA (D2T-RA) were defined as those with a history of using ≥2 biological/targeted synthetic (b/ts) disease-modifying antirheumatic drugs (b/tsDMARDs) who had moderate or high disease activity.
Int J Rheum Dis
November 2024
Aim: The objective of this study was to compare the clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis (RA).
Methods: This study included 274 patients treated with abatacept and 241 treated with baricitinib who were followed for >52 weeks. Potential treatment selection bias was addressed by using inverse probability of treatment weighting.
Osteoporos Sarcopenia
September 2024
Objectives: Locomotive syndrome (LS) leads to reduced physical function and a high risk of becoming bedridden. Grip strength serves as an indicator of upper limb and overall physical function. Rheumatoid arthritis (RA) patients with reduced grip strength frequently show finger and wrist joint inflammation.
View Article and Find Full Text PDFMod Rheumatol
December 2024
Objectives: This retrospective study aimed to examine the clinical features of juvenile onset ankylosing spondylitis (JoAS) in Japanese patients.
Methods: We examined clinical symptoms (including initial symptoms) and the progression to diagnosis of AS in 17 Japanese JoAS patients at Nagoya university hospital between January 2004 and May 2023. Initial symptoms considered were pain at axial joints and/or extra-axial joints.
Objectives: The aim of this study was to investigate the prevalence of social frailty and associated factors.
Methods: A total of 655 consecutive patients who were able to complete the Kihon Checklist (KCL) and the Questionnaire on Social Frailty between June and August 2022 were enrolled. Social frailty was assessed using the Makizako Social Frailty Index.
Objectives: The present study aimed to examine discrepancies between assessments based on Routine Assessment of Patient Index Data 3 (RAPID3) and Simple Disease Activity Index (SDAI) in rheumatoid arthritis (RA) patients with controlled disease activity.
Methods: Data from 464 RA patients in SDAI remission or low disease activity (REM/LDA) were analysed. Patient-reported outcome (PRO) measures, including Health Assessment Questionnaire Disability Index (HAQ-DI), 25-question Geriatric Locomotive Function Scale (GLFS-25), and Kihon checklist (KCL), were assessed.
Mod Rheumatol
October 2024
Int J Rheum Dis
January 2024
Objective: This study aimed to determine whether there are associations between laughter, disease activity, frailty, and depression in rheumatoid arthritis (RA) patients.
Methods: A total of 240 patients were included in this prospective cohort study on frailty in RA patients between March 2021 and June 2022. Patients were divided into the following four groups according to the frequency of laughter: "almost every day," "1-5 days per week," "1-3 days per month," and "never or almost never.
Background: This study aimed to investigate factors associated with frailty in rheumatoid arthritis (RA) patients.
Methods: A total of 656 RA patients were evaluated using data from an observational study in 2022. Among these patients, 152 with frailty were assigned to the frailty group, and 504 without frailty were assigned to the non-frailty group.
Objectives: To investigate a plateau in treatment enhancement for improving the frailty status of rheumatoid arthritis (RA) patients.
Methods: A total of 345 RA patients who were not robust in 2021 were assigned to the improved ("robust 2022," n = 51) and non-improved ("pre-frailty/frailty 2022," n = 294) groups. Factors associated with "robust 2022" were examined by logistic regression analysis.